MedTrace Logo

Apigenin in Increasing Health Benefits in High Risk Breast Clinic Patients

NCT03139227 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-09-13

No results posted yet for this study

Summary

This pilot clinical trial studies the side effects and best dose of apigenin in increasing health benefits in high risk breast clinic patients. Celery is high in apigenin, a compound that may have anti-cancer activities. Eating a celery-based diet may help in prevention and treatment of inflammatory diseases including cancer.

Conditions

  • Health Status Unknown

Interventions

PROCEDURE

Bio specimen Collection

Patients undergo collection of blood and urine

DIETARY_SUPPLEMENT

Dietary Intervention

Consume celery-banana bread

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Sagar Sardesai, MBBS · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2019-03-14
Completion
2019-03-14

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139227 on ClinicalTrials.gov